0.052
0.00 (0.00%)
| Penutupan Terdahulu | 0.052 |
| Buka | 0.053 |
| Jumlah Dagangan | 37,349,151 |
| Purata Dagangan (3B) | 79,634,533 |
| Modal Pasaran | 4,062,974 |
| Harga / Pendapatan (P/E TTM) | 0.000 |
| Harga / Jualan (P/S) | 0.010 |
| Harga / Buku (P/B) | 0.860 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Apr 2025 - 18 Apr 2025 |
| Margin Operasi (TTM) | -68,588.24% |
| EPS Cair (TTM) | 628.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -94.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 230.57% |
| Nisbah Semasa (MRQ) | 0.090 |
| Aliran Tunai Operasi (OCF TTM) | -13.92 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.59 M |
| Pulangan Atas Aset (ROA TTM) | -99.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -35,568.57% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Aditxt, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.83 |
|
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Institusi | 0.10% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |